利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

61 条记录 (耗时 0.045 秒)

    CELLULASE VARIANTS
    32.
    发明申请
    CELLULASE VARIANTS 审中-公开
    纤维素酶变体

    公开(公告)号：US20110250674A1

    公开(公告)日：2011-10-13

    申请号：US13162636

    申请日：2011-06-17

    申请人： Kim Vilbour Andersen ,  Martin Schülein ,  Torben Henriksen ,  Lars Christiansen ,  Bo Damgaard ,  Claus Von der Osten

    发明人： Kim Vilbour Andersen ,  Martin Schülein ,  Torben Henriksen ,  Lars Christiansen ,  Bo Damgaard ,  Claus Von der Osten

    IPC分类号： C12N9/42

    CPC分类号： C11D3/38645 ,  C12N9/2437 ,  C12Y302/01004

    摘要： The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of: a. constructing a multiple alignment of at least two amino acid sequences known to have three-dimensional structures similar to endoglucanase V (EGV) from Humicola insolens known from Protein Data Bank entry 4ENG; b. constructing a homology-built three-dimensional structure of the cellulolytic enzyme based on the structure of the EGV; c. identifying amino acid residue positions present in a distance from the substrate binding cleft of not more than 5 Å; d. identifying surface-exposed amino acid residues of the enzyme; e. identifying all charged or potentially charged amino acid residue positions of the enzyme; f. choosing one or more positions wherein the amino acid residue is to be substituted, deleted or where an insertion is to be provided; and g. carrying out the substitution, deletion or insertion by using conventional protein engineering techniques. Also described are cellulase variants obtained by this method.

    摘要翻译： 本发明涉及通过氨基酸取代，缺失或插入改进纤维素分解酶的性质的方法，该方法包括以下步骤：a。 构建已知具有类似于蛋白质数据库条目4ENG中已知的Humicola insolens的内切葡聚糖酶V（EGV）的三维结构的至少两个氨基酸序列的多重比对; b。 基于EGV的结构构建纤维素分解酶的同源构建的三维结构; C。 鉴定存在于与所述基质结合裂缝一定距离的氨基酸残基位置不大于5埃; d。 鉴定酶的表面暴露的氨基酸残基; e。 鉴定酶的所有带电荷或潜在带电的氨基酸残基位置; F。 选择其中氨基酸残基被取代，缺失或提供插入的一个或多个位置; 和g。 通过使用常规蛋白质工程技术进行取代，缺失或插入。 还描述了通过该方法获得的纤维素酶变体。

    G-CSF polypeptides and conjugates
    37.
    发明授权
    G-CSF polypeptides and conjugates 失效
    G-CSF多肽和缀合物

    公开(公告)号：US06646110B2

    公开(公告)日：2003-11-11

    申请号：US09760008

    申请日：2001-01-10

    申请人： Torben Lauesgaard Nissen ,  Kim Vilbour Andersen ,  Christian Karsten Hansen ,  Jan Moller Mikkelsen ,  Hans Thalsgard Schambye

    发明人： Torben Lauesgaard Nissen ,  Kim Vilbour Andersen ,  Christian Karsten Hansen ,  Jan Moller Mikkelsen ,  Hans Thalsgard Schambye

    IPC分类号： C07K100

    CPC分类号： A61K9/0019 ,  A61K38/00 ,  A61K47/42 ,  C07K14/535

    摘要： The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.

    摘要翻译： 本发明涉及多肽缀合物，其包含显示G-CSF活性的多肽，并且具有不同于至少一个指定的引入和/或去除的氨基酸残基中的人G-CSF的氨基酸序列的氨基酸序列，所述氨基酸残基包含用于 非多肽部分，并且具有连接到多肽的连接基团的至少一个非多肽部分。 连接基团可以例如是赖氨酸，半胱氨酸，天冬氨酸或谷氨酸残基或糖基化位点，并且非多肽部分可以例如是聚合物，例如聚乙二醇或低聚糖。 缀合物具有一个或多个改进的性质，例如增加的生物半衰期和减少的副作用。

    LONG ACTING BIOLOGICALLY ACTIVE LUTEINIZING HORMONE (LH) COMPOUND
    38.
    发明申请
    LONG ACTING BIOLOGICALLY ACTIVE LUTEINIZING HORMONE (LH) COMPOUND 有权
    长效生物活性胡萝卜素（LH）化合物

    公开(公告)号：US20140228292A1

    公开(公告)日：2014-08-14

    申请号：US14233455

    申请日：2012-07-09

    申请人： Peter Nordkild ,  Svend Lindenberg ,  Claus Yding Andersen ,  Kim Vilbour Andersen

    发明人： Peter Nordkild ,  Svend Lindenberg ,  Claus Yding Andersen ,  Kim Vilbour Andersen

    IPC分类号： C07K14/59 ,  C07K14/76

    CPC分类号： A61K47/48284 ,  A61K38/24 ,  A61K47/60 ,  A61K47/643 ,  A61K47/644 ,  A61K47/68 ,  C07K14/59 ,  C07K14/76 ,  C07K2319/31

    摘要： The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.

    摘要翻译： 本发明涉及一种长效生物活性黄体生成激素（LH）化合物，其包含与药学上可接受的分子连接的LH激动剂，所述LH激动剂提供LH激动剂或LH化合物的体内血浆半衰期，其与体内相比大大增加 以与LH化合物相同的方式施用LH激动剂的血浆半衰期。 本发明涉及用于受控卵巢刺激的方法，其可以与辅助生殖技术如体外受精，细胞内精子注射，子宫内子宫内受精和体外成熟结合使用。 在其他方面，本发明涉及诱导卵泡发生的方法以及为黄体提供黄体支持的方法。

    Factor VII or VIIa Polypeptide Variants
    39.
    发明申请
    Factor VII or VIIa Polypeptide Variants 审中-公开
    因子VII或VIIa多肽变体

    公开(公告)号：US20100260741A1

    公开(公告)日：2010-10-14

    申请号：US12707453

    申请日：2010-02-17

    申请人： Jesper Mortensen Haaning ,  Kim Vilbour Andersen

    发明人： Jesper Mortensen Haaning ,  Kim Vilbour Andersen

    IPC分类号： A61K38/48 ,  C12N9/96 ,  A61P7/04

    CPC分类号： C12N9/6437 ,  A61K38/00 ,  C12Y304/21021

    摘要： The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

    摘要翻译： 本发明涉及因子VII（FVII）或因子VIIa（FVIIa）多肽的新型多肽变体，其中所述变体包含位置10和32的氨基酸取代，并且其中所述变体还包含共价连接到引入 位于Gla结构域之外的体内N-糖基化位点。 这样的多肽变体可用于治疗，特别是用于治疗各种凝血相关疾病如创伤。

    Factor VII or VIIa polypeptide variants
    40.
    发明授权
    Factor VII or VIIa polypeptide variants 有权
    因子VII或VIIa多肽变体

    公开(公告)号：US07700733B2

    公开(公告)日：2010-04-20

    申请号：US10512754

    申请日：2003-04-29

    申请人： Jesper Mortensen Haaning ,  Kim Vilbour Andersen

    发明人： Jesper Mortensen Haaning ,  Kim Vilbour Andersen

    IPC分类号： A61K35/14

    CPC分类号： C12N9/6437 ,  A61K38/00 ,  C12Y304/21021

    摘要： The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

    摘要翻译： 本发明涉及因子VII（FVII）或因子VIIa（FVIIa）多肽的新型多肽变体，其中所述变体包含位置10和32的氨基酸取代，并且其中所述变体还包含共价连接到引入 位于Gla结构域之外的体内N-糖基化位点。 这样的多肽变体可用于治疗，特别是用于治疗各种凝血相关疾病如创伤。